ONF:如何提高非小细胞肺癌患者的服药依从性?

2015-07-06 MedSci MedSci原创

目的:该研究的目的在于探究癌症患者的口服药指导教育措施(在护士的指导干预下),对加强患者的化疗药相关知识并坚持服药是否有效,及其有效程度。研究中关于患者口服化疗药指导所使用的护理措施(MOATT)和教育工具已得到多国家医疗机构认可。方式:该研究为纵向、描述性、可行性研究。研究地点在一个动态胸部肿瘤疾病中心进行,该疾病中心位于波士顿的达纳法伯癌症研究所。参与人员为30位口服化疗药物埃罗替尼的肺癌患者

目的:该研究的目的在于探究癌症患者的口服药指导教育措施(在护士的指导干预下),对加强患者的化疗药相关知识并坚持服药是否有效,及其有效程度。研究中关于患者口服化疗药指导所使用的护理措施(MOATT)和教育工具已得到多国家医疗机构认可。

方式:该研究为纵向、描述性、可行性研究。研究地点在一个动态胸部肿瘤疾病中心进行,该疾病中心位于波士顿的达纳法伯癌症研究所。参与人员为30位口服化疗药物埃罗替尼的肺癌患者。我们参照MOATT标准,对患者进行了健康教育,培训指导后72小时内保持电话联系。在口服化疗药第一个周期结束后,参与人员完成知识评定量表(KRS)和第八版改良后的药物依从量表(MMAS-8)。我们观察的主要指标是患者对药物的认知程度和依从性、药物培训教育的可行性。

结果:从实验得知,27名患者两种量表得分均较高。结构式、护士指导下进行的对患者的化疗药物教育及后续的健康指导培训时间范围在14-30分钟。一些患者同研究人员保持了持续的联系,并询问药物的处方购买情况和引发的相关临床表现情况。参与人员通过临床表现,记录了出现较多的副作用表现。

结论:通过使用MOATT标准下的教育措施,我们对一些预备口服化疗药的肺癌患者进行了结构式、护士指导下进行的口服药服用指导,结果表明,该措施可行,可以在肿瘤中心普及应用,该措施对肿瘤中心的住院患者将会大有裨益,且对患者培训指导之后患者的服药依从性和对药物知识都有提高。我们需要进行目的是探索如何提高在家治疗的患者的服药依从性的进一步的研究。

对护理的启迪:与病人进行结构式访谈,并对他们进行药物使用指导,可以提高病人对口服化疗药的依从性,并可以使他们对药物的相关知识有了更进一步的了解。但我们仍需关注患者可能出现的药物副作用,并对他们进行心理护理。

原始出处:

Jean Boucher,Joan Lucca,Catherine Hooper,Lillian Pedulla,Donna L. Berry. A Structured Nursing Intervention to Address 
Oral Chemotherapy Adherence in Patients 
With Non-Small Cell Lung Cancer.ONF.2015, 42(4), 383-389 DOI: 10.1188/15.ONF.383-389

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (20)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2059507, encodeId=60fb205950e48, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Jun 15 06:49:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990547, encodeId=2343199054ef6, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 08 14:49:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31646, encodeId=885c3164689, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:32:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600806, encodeId=09431600806bc, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319254, encodeId=d8e813192540b, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31330, encodeId=37f5313304e, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31335, encodeId=c95f31335e6, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31334, encodeId=661c31334c1, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31332, encodeId=337a313321c, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31331, encodeId=54b3313316b, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2059507, encodeId=60fb205950e48, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Jun 15 06:49:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990547, encodeId=2343199054ef6, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 08 14:49:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31646, encodeId=885c3164689, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:32:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600806, encodeId=09431600806bc, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319254, encodeId=d8e813192540b, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31330, encodeId=37f5313304e, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31335, encodeId=c95f31335e6, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31334, encodeId=661c31334c1, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31332, encodeId=337a313321c, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31331, encodeId=54b3313316b, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2059507, encodeId=60fb205950e48, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Jun 15 06:49:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990547, encodeId=2343199054ef6, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 08 14:49:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31646, encodeId=885c3164689, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:32:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600806, encodeId=09431600806bc, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319254, encodeId=d8e813192540b, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31330, encodeId=37f5313304e, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31335, encodeId=c95f31335e6, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31334, encodeId=661c31334c1, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31332, encodeId=337a313321c, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31331, encodeId=54b3313316b, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=)]
    2015-07-08 huaxipanxing

    看看

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2059507, encodeId=60fb205950e48, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Jun 15 06:49:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990547, encodeId=2343199054ef6, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 08 14:49:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31646, encodeId=885c3164689, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:32:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600806, encodeId=09431600806bc, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319254, encodeId=d8e813192540b, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31330, encodeId=37f5313304e, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31335, encodeId=c95f31335e6, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31334, encodeId=661c31334c1, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31332, encodeId=337a313321c, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31331, encodeId=54b3313316b, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2059507, encodeId=60fb205950e48, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Jun 15 06:49:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990547, encodeId=2343199054ef6, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 08 14:49:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31646, encodeId=885c3164689, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:32:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600806, encodeId=09431600806bc, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319254, encodeId=d8e813192540b, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31330, encodeId=37f5313304e, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31335, encodeId=c95f31335e6, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31334, encodeId=661c31334c1, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31332, encodeId=337a313321c, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31331, encodeId=54b3313316b, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=)]
    2015-07-08 fyxzlh
  6. [GetPortalCommentsPageByObjectIdResponse(id=2059507, encodeId=60fb205950e48, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Jun 15 06:49:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990547, encodeId=2343199054ef6, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 08 14:49:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31646, encodeId=885c3164689, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:32:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600806, encodeId=09431600806bc, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319254, encodeId=d8e813192540b, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31330, encodeId=37f5313304e, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31335, encodeId=c95f31335e6, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31334, encodeId=661c31334c1, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31332, encodeId=337a313321c, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31331, encodeId=54b3313316b, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=)]
    2015-07-07 famous

    不错!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=2059507, encodeId=60fb205950e48, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Jun 15 06:49:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990547, encodeId=2343199054ef6, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 08 14:49:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31646, encodeId=885c3164689, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:32:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600806, encodeId=09431600806bc, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319254, encodeId=d8e813192540b, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31330, encodeId=37f5313304e, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31335, encodeId=c95f31335e6, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31334, encodeId=661c31334c1, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31332, encodeId=337a313321c, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31331, encodeId=54b3313316b, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=)]
    2015-07-07 famous

    不错!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2059507, encodeId=60fb205950e48, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Jun 15 06:49:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990547, encodeId=2343199054ef6, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 08 14:49:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31646, encodeId=885c3164689, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:32:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600806, encodeId=09431600806bc, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319254, encodeId=d8e813192540b, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31330, encodeId=37f5313304e, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31335, encodeId=c95f31335e6, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31334, encodeId=661c31334c1, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31332, encodeId=337a313321c, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31331, encodeId=54b3313316b, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=)]
    2015-07-07 famous

    不错!

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=2059507, encodeId=60fb205950e48, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Jun 15 06:49:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990547, encodeId=2343199054ef6, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 08 14:49:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31646, encodeId=885c3164689, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:32:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600806, encodeId=09431600806bc, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319254, encodeId=d8e813192540b, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31330, encodeId=37f5313304e, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31335, encodeId=c95f31335e6, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31334, encodeId=661c31334c1, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31332, encodeId=337a313321c, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31331, encodeId=54b3313316b, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=)]
    2015-07-07 famous

    不错!

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2059507, encodeId=60fb205950e48, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99381, encryptionId=2cc599381bd, topicName=非小细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e07307, createdName=lingaifan, createdTime=Wed Jun 15 06:49:00 CST 2016, time=2016-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990547, encodeId=2343199054ef6, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed Jun 08 14:49:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31646, encodeId=885c3164689, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=166, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Wed Jul 08 12:32:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1600806, encodeId=09431600806bc, content=<a href='/topic/show?id=973e99390a4' target=_blank style='color:#2F92EE;'>#非小细胞肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99390, encryptionId=973e99390a4, topicName=非小细胞肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2e0218815946, createdName=zxxiang, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319254, encodeId=d8e813192540b, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed Jul 08 01:49:00 CST 2015, time=2015-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31330, encodeId=37f5313304e, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=120, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31335, encodeId=c95f31335e6, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31334, encodeId=661c31334c1, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31332, encodeId=337a313321c, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=31331, encodeId=54b3313316b, content=不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e880105337, createdName=famous, createdTime=Tue Jul 07 08:13:00 CST 2015, time=2015-07-07, status=1, ipAttribution=)]
    2015-07-07 famous

    不错!

    0

相关资讯

BBC:肺癌治疗的里程碑新发现

2015年5月30日,据BBC新闻报道的一项新近研究称,肺癌治疗可使一些患者的生存期加倍,实属里程碑式的新发现。        Nivolumab可使隐藏与人体正常防御系统之下的癌细胞无所遁形,让其接受人体免疫系统的自发处理。        该结果来自纳入582例癌症患者的研究结论,在美国临床肿瘤学

ACS指南:所有肺腺癌患者都需基因检测

ASCO最近认可了一项指南,确定了哪些肺癌患者需要进行基因检测测试评估,最显著的是陈述了所有的肺腺癌(或具有肺腺癌成分的混合肺癌)患者都应该接受表皮生长因子受体(EGFR)和间变性淋巴瘤激酶(ALK)的检测。无论患者的性别、种族和吸烟习惯如何都应该进行上述测试。因为基因检测能帮助制定针对肺癌患者的个体化的治疗方案,并且改善晚期肺癌患者的预后”。因为EGFR靶向药物如厄罗替尼和阿法替尼,ALK靶向药

ONF:哪种戒烟手册对肺癌患者家属戒烟效果棒棒哒?

目的:该研究的目的在于探索创新出一种具有性别特异性、且可以通过情感抚慰和亲情教育等相关因素,进而起到鼓励肺癌患者的相关家属成功戒烟的效果。方式:该研究为定性、描述性研究。实验地点在加拿大六个城市进行,参与人员为30名准备近期戒烟、或已经成功戒烟的肺癌患者的家属。这种戒烟手册通过采用语言和图片的形式强调家庭成员及亲属关系的重要性,并且根据戒烟者性别的不同而进行不同的讨论和指导,从而鼓励肺癌患者家属戒

PNAS:携带siRNA纳米颗粒可抑制肺癌细胞

RNA干扰(RNAi)是一种很有前途的方法,可以用来作为针对人体不同疾病(如癌症)的治疗策略。然而,在体内,如何将小分子siRNA转移到肿瘤或者癌细胞聚集的区域一直是很难的课题。通过一种高效的自组装系统,来自美国哈佛医学院和中国四川大学华西医学院的课题组,发展了一套独特的纳米颗粒平台,通过由固体多聚阳离子脂类和脂类-多聚乙二醇构成的分子外壳,包裹着小分子siRNA的运输系统。 在465个非小细胞

ONF:与性别相关的健康教育手册促使肺癌患者戒烟效果更好

目的:该研究的目的在于收集一种通过革新且与性别相关的宣传教育手册的有效性,该手册采用情感激励手段及其相关因素用于鼓励肺癌病人戒烟。方式:该研究为定性、描述性研究。实验在加拿大六个城市进行。参与人员为30个近期戒烟的肺癌患者。我们使用宣传手册分别对男性和女性患者用交谈和图片教育进行宣传教育,强调家庭成员的作用和他们的性别反思,使他们具有戒烟的勇气和信心,起到激励的作用。我们分别给男性和女性肺癌患者予

美国医院肺癌放疗全新技术

什么是放疗治疗?  放疗治疗是一个医疗过程,用高能量的放射线杀死肿瘤细胞,并缩小肿瘤。  放疗是如何起作用的?  高能射线破坏细胞中的DNA,导致他们死亡或停止分裂。因此癌细胞比正常细胞分裂更快,他们更加容易被破坏,更易受到攻击。健康细胞也会受到影响,但是能够更好的修复这种破坏。  什么时候适合使用放疗?  小细胞肺癌和非小细胞肺癌经常用放疗进行治疗,放疗经常与化疗,或外科手术,或者两者一起,联合